Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL645409 | 0.69 | EPHX2 (0.62) | LMNAEPHX2TSHRALDH1A1KDM4E | |
| SCHEMBL19542362 | 0.68 | EPHX2 (0.64) | EPHX2TSHRKDM4EHTT | |
| SCHEMBL7109117 | 0.66 | LMNA (0.38) | LMNAEPHX2TSHRGPR84ALDH1A1 | |
| SCHEMBL16861239 | 0.66 | GBA1 (0.34) | GBA1LMNAEPHX2NAAATSHR | |
| SCHEMBL28153842 | 0.66 | NPC1 (0.48) | GBA1LMNANAAAALDH1A1 | |
| SCHEMBL23257829 | 0.64 | TSHR (0.45) | LMNAEPHX2TSHRGPR84 | |
| SCHEMBL27597851 | 0.64 | NPC1 (0.47) | GBA1LMNANAAAALDH1A1 | |
| Methane SCHEMBL27666784 | 0.64 | NPC1 (0.47) | GBA1LMNANAAAALDH1A1 | |
| SCHEMBL28050144 | 0.64 | LMNA (0.36) | GBA1LMNANAAAALDH1A1KDM4E | |
| SCHEMBL8393327 | 0.63 | GBA1 (0.42) | GBA1LMNAEPHX2NAAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246470-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2019-04-02 | — | — | US | disclosed |
| US-20180346486-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2018-12-06 | — | — | US | disclosed |
| US-10011609-B2 | Heterocyclic compounds | CADILA HEALTHCARE LIMITED (IN) | 2018-07-03 | — | — | US | disclosed |
| EP-3068788-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Cadila Healthcare Limited (IN) | 2016-09-21 | — | — | EP | disclosed |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2016-09-08 | — | — | US | disclosed |
| CN-105722841-A | Novel Heterocyclic Compounds | 卡迪拉保健有限公司 | 2016-06-29 | — | — | CN | disclosed |
| WO-2015097713-A1 | NOVEL HETEROCYCLIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011609-B2 | Heterocyclic compounds | GPR55, GPR68, GPR65 | ADRB1 30/4885GBA1 2670/4885LMNA 2902/4885 |
| US-20180346486-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HK1, HAAO, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB1 3006/4885GBA1 1066/4885LMNA 3259/4885 |
| US-10246470-B2 | Heterocyclic compounds | HAAO, HK1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB1 3143/4885GBA1 964/4885LMNA 2083/4885 |
| US-20160257701-A1 | NOVEL HETEROCYCLIC COMPOUNDS | GPR55, GPR68, GPR65 | ADRB1 25/4885GBA1 2644/4885LMNA 3125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.